Yu Xin, Li Zheng, Shen Jianxiong
Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing 100042, China.
Department of Orthopedics Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100042, China.
Am J Transl Res. 2016 Feb 15;8(2):742-8. eCollection 2016.
BRD7 (bromodomain 7), also known as celtix-1, was first identified in nasopharyngeal carcinoma (NPC) cells in 2000. BRD7 is a crucial component of both functional p53 and BRCA1 (breast cancer 1, early onset) pathways. Recently, the BRD7 tumor suppressor status has been fully established. Previous studies demonstrated that BRD7 was downregulated in human breast cancer and the downregulation often associates with tumor progression. The expression of BRD7 was downregulated in various cancers, including breast cancer, NPC, gastric cancer, colorectal carcinoma, ovarian cancer, and prostate cancer. Moreover, BRD7 inhibited cancer cell growth and metastasis and promote apoptosis in vitro and in vivo via downregulating AKT pathway. In addition, BRD7 may regulate many signaling pathways including ras-raf-MEK-ERK and RB/E2F. In this review, we provide an overview of current knowledge concerning the role of BRD7 in tumor development and progression. To our knowledge, this is the first review about the role of this novel tumor suppressor gene BRD7in tumor development and progression.
BRD7（溴结构域7），也被称为celtix-1，于2000年首次在鼻咽癌（NPC）细胞中被发现。BRD7是功能性p53和BRCA1（乳腺癌1，早发型）通路的关键组成部分。最近，BRD7的肿瘤抑制状态已得到充分确立。先前的研究表明，BRD7在人类乳腺癌中表达下调，且这种下调常与肿瘤进展相关。BRD7在包括乳腺癌、鼻咽癌、胃癌、结直肠癌、卵巢癌和前列腺癌在内的多种癌症中表达均下调。此外，BRD7在体外和体内通过下调AKT通路抑制癌细胞生长和转移并促进细胞凋亡。另外，BRD7可能调节包括ras-raf-MEK-ERK和RB/E2F在内的许多信号通路。在本综述中，我们概述了目前关于BRD7在肿瘤发生和进展中作用的相关知识。据我们所知，这是关于这种新型肿瘤抑制基因BRD7在肿瘤发生和进展中作用的首次综述。
